MARKET

ACOR

ACOR

Acorda
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.100
-0.270
-11.39%
After Hours: 2.120 +0.02 +0.95% 18:52 01/24 EST
OPEN
2.420
PREV CLOSE
2.370
HIGH
2.480
LOW
2.100
VOLUME
2.90M
TURNOVER
--
52 WEEK HIGH
17.41
52 WEEK LOW
1.490
MARKET CAP
100.86M
P/E (TTM)
-0.2903
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ACOR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ACOR News

  • Implied Volatility Surging for Acorda (ACOR) Stock Options
  • Zacks.1d ago
  • Acorda -4.2% as holders file to offer 9.6M shares
  • seekingalpha.01/16 04:19
  • Acorda Therapeutics Files For ~9.6M Share Common Stock Offering By Selling Shareholders
  • Benzinga.01/15 21:22
  • Mid-Afternoon Market Update: OrganiGram Rises Following Q1 Results; Nektar Therapeutics Shares Plummet
  • Benzinga.01/15 19:10

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About ACOR

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.
More

Webull offers Acorda Therapeutics Inc (ACOR) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.